STALICLA’s innovative approach
STALICLA has developed Databased Endophenotyping Patient Identification, an innovative algorithm platform based on big data to bring precision medicine to subtypes of ASD patients.
- In the last five years, there has been an important shift towards sub-typing of diseases using genetics, molecular markers and big data analytics. Some cancers can now be precisely subtyped allowing clinicians to treat them in a highly targeted and ‘personalized’ way.
- Over the past 10 years, preclinical and clinical evidence has accumulated, pointing towards alterations in molecular pathways that lead to abnormal cell functioning in ASD. At STALICLA, we are looking to correct these alterations by repurposing targeted pharmacological treatments. This is our strategy to change the paradigm in ASD drug development.
Databased Endophenotyping Patient Identification identifies links between ASD-related and non-ASD biomedical research data. The results are filtered with non-behavioral clinical sets of signs and symptoms. This permits the identification of specific biomarkers. Possible therapeutic targets are generated and then compared with existing drugs repositories. This results in the identification of potentially repurposable drugs.